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Abstract 
Tumor microenvironment (TME) plays an integral part in the biology of cancer, participating in tumor initiation, 
progression, and response to therapy. Exosome is an important part of TME. Exosomes are small vesicles formed in 
vesicular bodies with a diameter of 30–100 nm and a classic “cup” or “dish” morphology. They can contain microRNAs, 
mRNAs, DNA fragments and proteins, which are shuttled from a donor cell to recipient cells. Exosomes secreted from 
tumor cells are called tumor‑derived (TD) exosomes. There is emerging evidence that TD exosomes can construct 
a fertile environment to support tumor proliferation, angiogenesis, invasion and premetastatic niche preparation. 
TD exosomes also may facilitate tumor growth and metastasis by inhibiting immune surveillance and by increasing 
chemoresistance via removal of chemotherapeutic drugs. Therefore, TD‑exosomes might be potential targets for ther‑
apeutic interventions via their modification or removal. For example, exosomes can serve as specific delivery vehicles 
to tumors of drugs, small molecules, or agents of prevention and gene therapy. Furthermore, the biomarkers detected 
in exosomes of biological fluids imply a potential for exosomes in the early detection and diagnosis, prediction of 
therapeutic efficacy, and determining prognosis of cancer. Although exosomes may serve as cancer biomarkers and 
aid in the treatment of cancer, we have a long way to go before we can further enhance the anti‑tumor therapy of 
exosomes and develop exosome‑based cancer diagnostic and therapeutic strategies.
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Background
Malignant tumors are complex structures that consist of 
cancer cells and the surrounding tumor stroma, which 
includes fibroblasts, immune cells, and endothelial cells. 
These surrounding cells are constantly releasing factors 
that directly or indirectly modify the tumor microenvi-
ronment (TME). The composition and characteristics 
of the TME are widely different [1]. TME plays an inte-
gral part in the biology of cancer, participating in tumor 
initiation, progression, and response to therapy. Factors 
released by tumor cells themselves contribute in creating 
an environment mostly favorable but sometimes detri-
mental to the tumor. [2]. Emerging evidence suggests that 
cellular and molecular components of TME and how they 
affect tumor initiation, progression, and advancement 
have become an imminent concern in cancer research. 
Moreover, events and molecules implicated in the cross 
talk between cancer cells and TME have emerged as 
attractive targets in anticancer intervention [3]. There-
fore, understanding and control of TME is important for 
the prevention, diagnosis and treatment of malignant 
tumors.
Recently, studies find that exosomes may play a pivotal 
role among cancer cells and the cells in TME. Exosomes, 
firstly identified three decades ago in reticulocytes, are 
30–100  nm in diameter and 1.13–1.19  g/mL in density, 
with a classic “cup” or “dish” morphology [4]. It is gener-
ally agreed that exosomes originate from multivesicular 
bodies and are released into the extracellular milieu upon 
the docking and fusion of multivesicular bodies with the 
plasma membrane [5]. To date, we experienced three 
breakthroughs in the cognition process of exosomes. 
Exosomes were initially considered as garbage bags 
for abandoned membrane parcels and molecular frag-




*Correspondence:  wangzhensurgeon@163.com; gxhans@163.com 
Department of Gastrointestinal Surgery, The First Affiliated Hospital 
of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, 
Guangxi Zhuang Autonomous Region, China
Page 2 of 9Wang et al. J Transl Med  (2016) 14:297 
the function of the immune system in the mid-1990s [6]. 
Secondly, researchers found that microRNAs (miRNAs), 
messenger RNAs (mRNA), DNA fragments and proteins 
could be loaded as “goods” in exosomes in the 2010s [7]. 
Thirdly, exosomes were found to function as “commu-
nication shuttles” between cells and transduct signals in 
recent years, which could re-encode genes of target cells 
and play a part in the development, invasion, metastasis 
and drug resistance of cancer [8].
In this review, we will discuss that exosomes can be 
served as a transporter in cancer development and pro-
gression, and can be used as a novel diagnostic and prog-
nostic biomarker in clinics.
Characteristics of exosomes
Biogenesis, structure and contents of exosomes
In contrast with larger microvesicles, which are directly 
shed from the plasma membrane, exosomes originate 
from multivesicular bodies (MVB) within the endocytic 
system and are released into the extracellular milieu 
upon the docking and fusion of the MVB with the plasma 
membrane. The mechanism that meditates exosomal bio-
genesis remains elusive and may vary depending on cell 
types and functional contexts [4]. However, It is generally 
agreed that exosomes formation and release is regulated 
by the “endosomal sorting complexes required for trans-
port” (ESCRT). In addition, members of the Rab GTPase 
(guanosine triphosphate) family (such as Rab11 and 
Rab27) are also important for MVB trafficking and exo-
some secretion [9].
As revealed by the transmission electron microscope 
(TEM) images, exosomes are typically cup-shaped extra-
cellular vesicles with 30–100  nm diameter, composed 
by a lipid bilayer containing membrane proteins that 
surrounds a lumen comprising a broad range of bio-
molecules (such as carbohydrates, DNA and RNA). The 
composition of exosomes vary according to cell type and 
mechanism of biogesesis. To date, multiple proteins, 
mRNAs, and miRNAs have been identified in exosomes 
derived from different tissues [10]. These biomolecules 
packed into the lumen of exosomes mirror the content 
of cells from which the exosomes originated. Further-
more, exosome-carried biomolecules can be transferred 
to remote sites to regulate the function of distant cells 
and may affect the processes of receptor cells, especially 
by promoting interaction between various cells in the 
tumor microenvironment [11]. Therefore, exosomes play 
an important role in cancer development.
Isolation and analysis of exosomes
To date, various methods are available for the isolation 
of exosomes, including ultracentrifugation, sucrose gra-
dient ultracentrifugation combined with ultrafiltration 
centrifugation (SGUUC), magnetic activated cell sorting 
(MACS) and commercial kits. According to the require-
ments of the experiment, different methods can be used. 
Ultracentrifugation or SGUUC can be used when the 
sample is ample, and exosomes are abundant; otherwise, 
MACS and commercial kits can be used. Next, TEM can 
be used for shape and size analysis. Furthermore, western 
blot and flow cytometry (FCM) are usually used in the 
identification of exosomes by detecting specific tetras-
panins (such as CD9, CD63 and Hsp 70). Finally, nucleic 
acid sequencing, western blot or ELISA can be used for 
exosome RNA and protein identification in the follow-up 
study.
Exosomes and cancer
Role of exosomes in cancer growth
Exosomes secreted from tumor cells are called tumor-
derived (TD) exosomes. TD exosomes may modulate the 
local growth of cancer via autocrine signals provided by 
exosomes. Autocrine effects of exosomes vary with cell 
types and cellular characteristics. For example, auto-
crine signals mediated by exosomes from the non-small 
cell lung cancer cell lines, glioma cells and gastric cancer 
cell lines increased cellular proliferation by increasing 
phosphorylation of Akt and extracellular signal regu-
lated kinase, which, with other downstream molecules, 
are associated with cellular proliferation [12–14]. Addi-
tionally, heat shock proteins (HSP70 and HSP90) and 
survivin may be increased in exosomes because of cel-
lular stresses. These proteins may inhibit apoptosis and 
increase cellular proliferation so they provide a strong 
stimulus to the microenvironment that can facilitate the 
growth of cancers [15, 16]. Oppositely, exosomes from 
human pancreatic cancer can increase the expression of 
Bax but decrease the expression of Bcl-2, resulting in the 
steering of tumor cells to the mitochondrial apoptotic 
pathway [17]. This suggested that TD exosomes might 
play potential anti-tumor role by inducing apoptosis in 
some cancers. Therefore, whether TD exosomes in  vivo 
are beneficial or harmful to their own survival depends 
on the cell types and cellular characteristics, which needs 
to be elucidated further.
Role of exosomes in angiogenesis
The angiogenic process inherent to the cancer progres-
sion is a procedure of neovascular formation from pre-
existing blood vessels, which is caused by numerous 
interactions between regulators, mediators, and stimu-
latory molecules. Vascular endothelial growth factors 
(VEGF), fibroblast growth factor (FGF), transform-
ing growth factor β (TGF-β), and IL-8 are some of the 
angiogenic factors that act on the regulation of migra-
tion and proliferation of endothelial cells, required for 
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the stimulation of angiogenesis. Recently, the ability of 
TD exosomes to induce angiogenesis in various can-
cers and tumour microenvironments has been well 
documented. Katoh et  al. found that exosomes released 
under hypoxic conditions contribute to the stimulation 
of angiogenesis [18]. Granulocyte macrophage colony 
stimulating factor (GM-CSF) induces hypoxia inducible 
factor 1 alpha (HIF-1α) in macrophages, and HIF-1α pro-
motes neoangiogenesis. Hood JL found that melanoma 
exosomes could facilitate angiogenesis by inducing GM-
CSF expression by endothelial cells in  vitro and HIF-1α 
expression in pre-metastatic lymph nodes in  vivo. This 
suggest a relationship between melanoma exosome 
induced endothelial GM-CSF and macrophage medi-
ated angiogenesis in lymph nodes [19]. Src, which sig-
nals through focal adhesion kinase (FAK) in response to 
integrin activation, has been implicated in many aspects 
of tumor biology, including angiogenesis. DeRita et  al. 
found that exosomes derived from the androgen recep-
tor (AR)-positive prostate cancer cell line C4-2B, which 
are in rich in c-Src, could promote tumor angiogenesis 
[20]. Wang et al. reported that murine multiple myeloma 
exosomes which carried multiple angiogenesis-related 
proteins, enhanced angiogenesis and directly promoted 
endothelial cell growth by modulating several pathways 
such as signal transducer and activator of transcrip-
tion 3 (STAT3), c-Jun N-terminal kinase, and p53. As a 
result, they concluded that multiple myeloma exosomes 
modulate the bone marrow microenvironment through 
enhancement of angiogenesis [21]. Further, Taraboletti 
et  al. reported that matrix metalloproteinases (MMPs) 
within exosomes derived from endothelial cells were 
functionally active, and led to endothelial cell invasion 
and capillary-like structure formation [22]. Addition-
ally, recent evidence highlights that proangiogenic RNAs 
(including mRNAs and miRNAs) within exosomes from 
cancer cells can induce angiogenesis and contribute to 
prompting the angiogenic switch [23]. Quantitative pro-
teomics further revealed that proteins (such as Alix, and 
tetraspanins) within TD exosomes facilitated angiogene-
sis [24]. These suggested that exosomes have the ability to 
facilitate angiogenesis by inducing cell signalling between 
cells.
Role of exosomes in cancer invasion and metastasis
A central process in the metastatic cascade is cell inva-
sion and migration, whereby disseminating cancer 
cells extravasate into distant sites and colonize second-
ary tissues and organs. Recent evidence highlights that 
TD exosomes may contribute to cancer invasion and 
metastasis by regulating stromal cells, remodeling the 
extracellular matrix (ECM) and stimulating angiogen-
esis [12]. TD-exosomes can induce changes in fibroblasts 
indicative of a transition to myofibroblasts. Myofibro-
blasts then may modulate the microenvironment (such 
as degradation of the ECM and increased production of 
pericellular hyaluronic acid) to facilitate the invasion of 
cancer cells [25]. Recently, exosomes derived from mes-
enchymal stem cells were shown to enhance the inva-
sion and migration of human gastric cancer-27 cells via 
the induction of the epithelial–mesenchymal transition, 
which was achieved by activating the protein kinase B 
signaling pathway [14]. Further, studies reported that 
exosomes from colorectal cancer contain full length, 
signalling-competent epidermal growth factor recep-
tor (EGFR) ligands. The invasive potential of colorectal 
cancer cells was found to be directly related to the con-
centration of exosomes containing the EGFR ligand, 
amphiregulin, suggesting that exosome-mediated ligand 
transfer contributes to cancer invasiveness and metasta-
sis [26]. Additionally, exosomes derived from 21D1 were 
shown to be enriched with MMPs (such as MMP-1 and 
MMP-19) [27]. MMPs are capable of degrading ECM 
components, such as gelatin fibronectin and collagen, 
and correlate with high grade of cancer invasion [28]. 
These suggest that exosomes can enhance the degrada-
tion of ECM and promote the invasion of cancer cells to 
the matrix.
Metastasis formation is a complex process including (a) 
The degradation and remodeling of the ECM; (b) The for-
mation of new blood vessels. Metastatic niche formation 
also requires exosomes. TD exosomes can participate 
actively in shaping a premetastatic niche by transport-
ing several biologically active molecules that play impor-
tant roles in the process of metastatic niche formation. 
Exosomal proteins with a positive effect on the invasive 
behavior of cancer cells, including MMPs, VEGF, and 
tetraspanins, can promote cell migration, cell spreading, 
and cable formation by regulating integrin compartmen-
talization, internalization, recycling, and signaling [23, 
29, 30]. In addition to enhancing the invasiveness of can-
cer cells, TD exosomes contribute to the establishment 
a metastatic niche via the delivery of proteins (such as 
VEGF, FGF, and TGF-β) and RNAs (such as mRNAs and 
miRNAs) that support angiogenesis [30, 31].
Role of exosomes in tumor immunity
The proteins in an exosome are exactly similar to the 
proteins in its parallel cells and are cell-type specific. 
TD exosomes contain tumor-specific antigens that are 
expressed in the parent cells. Compared with the total cell 
lysates, the tumor antigens (such as carcinoembryonic 
antigen and mesothelin) in exosomes are more abun-
dant. Currently, TD exosomes are being used as a source 
of tumor antigen to stimulate dendritic cells (DCs), lead-
ing to the transfer of tumor antigens to DCs and inducing 
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CD8+  T cell dependent anti-tumor effects [32]. For 
example, miRNAs (such as miR-21 and miR-29a) trans-
ported by TD exosomes may act like ligands by binding to 
toll-like receptors and trigger the inflammatory response 
[33]. Recently, Besse et al. carried out a phase II clinical 
trial testing the clinical benefit of IFN (interferon)-γ-
Dex (dendritic cell-derived exosomes) loaded with MHC 
(major histocompatibility complex) class I- and class 
II-restricted cancer antigens as maintenance immuno-
therapy after induction chemotherapy in patients bearing 
inoperable non-small cell lung cancer (NSCLC) without 
tumor progression. As a result, they found an increase in 
NKp30-dependent NK (natural killer) cell functions in a 
fraction of these NSCLC patients presenting with defec-
tive NKp30 expression. This phase II trial confirmed the 
capacity of Dex to boost the NK cell arm of antitumor 
immunity in patients with advanced NSCLC [34]. There-
fore, the pro-immunogenic potential was identified as a 
key property of TD exosomes.
Via its normal functions, the immune system should 
minimize the progression and development of cancers; 
however, cancers were found to inhibit immune sur-
veillance, leading to their more rapid growth, progres-
sion and dissemination [21]. Specifically, cancer cells 
have rapid growth after reception of exosomes isolated 
from matching malignant lesions [12–14]. Recently, 
exosomes were found to inhibit immunity by increasing 
the immune suppressive cells, minishing the proliferation 
and cytotoxicity of NK and T cells, and decreasing the 
number and functions of antigen presenting cells [35–
37]. This implies that the decrease in immunity caused by 
neoplastic lesions is primarily mediated by TD exosomes 
[38].
Therefore, it is the balance of the activation level and 
abundance of the immune mediators and modulators in 
the tumor microenvironment that dictates if the inflam-
matory tumor response or anti-tumor immunity occurs. 
And exosomes have significant roles in this equilibrium.
Role of exosomes in drug resistance
Exosomes normally function in the export of waste prod-
ucts and less-needed molecules from cells. Recently, 
many studies evaluated the role of exosomes in drug 
resistance of cancers. Safaei et al. reported that the accu-
mulation of cisplatin in the lysosomal compartment of 
human ovarian cancer cell lines is significantly reduced 
owing to the release of exosomes [39]. Also, the amount 
of cisplatin in exosomes released from cisplatin-resistant 
cells is 2.6 times higher than from cisplatin-sensitive cells 
after treatment with cisplatin. A similar phenomenon 
was also observed with melanosome [40]. These sug-
gested that many anticancer drugs can be encapsulated 
in exosomes and effluxed outside of cells, and shedding 
of exosomes is closely related to drug resistance in many 
cancers.
In order to illuminate the mechanisms of exosomes 
in drug resistance, plenty of studies emerges in recent 
years. Lv et al reported that transport of MDR (multiple 
drug resistance)-1/P-gp by exosomes becomes a primary 
driver of docetaxel resistance in breast cancer models 
[41]. Au Yeung et  al. found that miR21 was transferred 
from cancer-associated adipocytes or fibroblasts to the 
cancer cells, where it suppressed ovarian cancer apop-
tosis and conferred paclitaxel resistance by binding to 
its direct novel target, apoptotic protease activating fac-
tor-1 (APAF1) [42]. Further, exosomes from HER2-over-
expressed breast cancer cell lines also contain full-length 
HER2 (human epidermal growth factor receptor-2) mol-
ecules, and can be combined with the HER2 antibody 
trastuzumab both in vivo and in vitro [43]. The exosome 
antibody interactions inhibit the anti-proliferative effects 
of trastuzumab by preventing it from binding to tumor 
cells, indicating that exosomes play a major role in the 
communication between cancer cells and can be used as 
vector-carried predictive markers and new therapeutic 
drugs.
The above studies support the viewpoint that the exclu-
sion of drugs by exosomes will result in a reduction of 
drugs in tumors, suggesting that TD exosomes can be 
used as a pathway of chemoresistance of specific cancer 
cells to specific drugs. However, more research is needed 
to clarify this new mechanisms of drug efflux.
Clinical utility of exosomes in cancer
The molecular features of TD exosomes mirror many of 
the molecular features of the tumors from which they 
originate. It was reported that TD exosomes contain bio-
markers characteristic of tumors, including those of the 
stomach, brain, colorectum, bladder, kidney, and mela-
nomas, so the presence of biomarkers characteristic of 
tumors in exosomes of biological fluids may aid in clinical 
decisions, including risk assessment, diagnosis, guiding 
treatment and determining prognosis. Of special impor-
tance is that exosomes are carried in blood and are shed 
into biological fluids, such as ascites and pleural fluids, all 
of which can be obtained easily for clinical use [44].
Use of exosomes in cancer diagnosis
As discussed above, exosomes derived from cancer cells 
are enriched with proteins, mRNA, and miRNA that 
are more abundant in cancer cells than in normal cells 
[45]. Thus, exosomes may be used as biomarkers in the 
diagnosis of cancer. Several studies found that exosomes 
derived from specific tumors can be used as biomarkers 
for cancer diagnosis by using the method of proteomics 
and transcriptomics [46, 47]. For example, Vardaki et al. 
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compared the proteomic content of exosomes derived 
from metastatic and non-metastatic human (MCF7 and 
MDA-MB-231) and mouse (67NR and 4T1) cell lines, 
and they identified periostin as a protein that is enriched 
in exosomes secreted by metastatic cells and validated its 
presence in a pilot cohort of breast cancer patient sam-
ples with localized disease or lymph node metastasis 
[48]. By profiling of human lncRNAs in prostate cancer 
and their exosomes from five different cell lines, Ahadi 
et  al. identified a list of statistically significant prostate 
cancer lncRNAs which are differentially expressed in the 
exosomes compared to their parent cell lines [49]. These 
unique signatures make exosomes a potential tool for 
cancer detection.
Additionally, biological molecules characteristic of can-
cers can be detected in exosomes derived from various 
bodily fluids, such as serum, urine, saliva and malignant 
ascites. For example, Taylor and Gercel-Taylor observed 
that the levels of 8 microRNAs are of diagnostic value 
in ovarian cancer. They found that these microRNAs 
could be detected in circulating exosomes in the serum 
of patients, and the levels of the microRNAs found in 
the exosomes were similar to those found in the cancer 
cells, suggesting an effective way to diagnose ovarian 
cancer even in asymptomatic patients [50]. As an onco-
gene, full length EGFR has been identified in exosomes 
isolated from prostate cancer cells and prostate cancer 
patient serum, which suggested that presence of exoso-
mal EGFR in prostate cancer patient exosomes may pre-
sent a novel approach for measuring of the disease state 
[51]. Furthermore, Machida et  al. tested the expression 
of four miRNAs (miR-1246, miR-3976, miR-4306, and 
miR-4644) in salivary exosomes from patients with pan-
creatobiliary tract cancer, as a result, they found that 
miR-1246 and miR-4644 were significantly higher in the 
cancer group than those in the control group. With the 
combination of miR-1246 and miR-4644, the area under 
receiver operating characteristic curve reached up to 
0.833, which showed that miR-1246 and miR-4644 in sal-
ivary exosomes could be candidate biomarkers for pan-
creatobiliary tract cancer [52]. These evidence imply that 
bodily fluid derived exosomes could be a noninvasive tool 
for the early diagnosis of cancer. And more studies are 
needed to evaluate the feasibility of bodily fluid derived 
exosomes for cancer diagnosis.
Use of exosomes in cancer therapy
To date, several clinical studies reported the role of 
exosomes in cancer therapy, and few major adverse 
effects were reported.
Firstly, because TD exosomes play an important role 
in cancer growth, metastasis and drug resistance, we 
can surpass this negative effect in cancer treatment 
by impairing the secretion of exosomes or removing 
exosomes from the blood circulation. Ostrowski et  al. 
found that knockdown of Rab27 or their effectors, SYTL4 
and EXPH5, could inhibit secretion of exosomes in HeLa 
cells [53]. GW4869S, a chemical inhibitor of sphingomy-
elinase 2 (which regulates the biosynthesis of ceramide 
and triggers the inward budding of exosomes from the 
limiting membrane of multivesicular endosomes), can 
inhibit exosome mediated tumor growth and metastasis 
[33]. Furthermore, Gamperl et  al. found that tinzaparin 
(a low-molecular-weight heparin) induced tissue factor 
pathway inhibitor (TFPI) release from tumor cells, and 
recombinant TFPI inhibited tumor exosomes induced 
tumor cell migration [54]. Recently, to remove exosomes 
from the blood circulation, a therapeutic hemofiltration 
approach called ADAPT™ (adaptive dialysis-like affinity 
platform technology) was derived. As a patient’s blood 
passes through ADAPT™ system, plasma components 
through the porous fibers and interact with the immobi-
lized affinity agents to which target molecules are selec-
tively adsorbed while blood cells and unbound serum 
components pass through the system. Thus, the capabil-
ity for removing circulating exosomes of ADAPT™ could 
offer a unique strategy for improving the therapeutic out-
comes for cancer patients [55]. However, since exosome 
production is determined by the size and growth rate of 
the tumor [55], the duration and frequency of ADAPT™ 
therapy would require optimizing to achieve a clinically 
beneficial level of circulating exosome depletion. The 
device strategy could also be tailored for different types/
stages of cancer and using devices incorporating differ-
ent affinity agents. Currently, although a spectrum of 
biologic effects of cancer exosomes have been identified 
in  vitro and experimental animals, the impact of clear-
ing exosomes therapeutically must still be evaluated the 
potential efficacy in promoting immune recovery and 
hindering tumor growth in a clinical setting.
Secondly, exosomes can be used as delivery vehicles 
loaded with various anticancer drugs, miRNAs, and siR-
NAs. In principle, exosomes used as drug delivery vehi-
cles have multiple advantages over existing synthetic 
systems: (1) As exosomes can be derived from autologous 
tumor cells, they may be less immunogenic than artifi-
cial delivery vehicles, thus probably leading to minimal 
toxicities when being transferred into target cells. (2) 
Exosomes have phospholipid bilayers, which may directly 
fuse with the target cell plasma membrane, thus improve 
the cellular internalization of the encapsulated drug. (3) 
The naturally small size of exosomes allows them to avoid 
phagocytosis by the mononuclear phagocyte system 
and facilitates their extravasation through tumor vessels 
and their subsequent diffusion in tumor tissues. Several 
studies have described the successful delivery and tumor 
Page 6 of 9Wang et al. J Transl Med  (2016) 14:297 
inhibition effect of TD exosomes. For example, exosome-
delivered tumor suppressor miRNAs, miR-143, and let-
7a, inhibited the growth of prostate and breast cancer 
in vivo, respectively. No adverse effects were observed in 
normal prostatic epithelial cells after treatment with exo-
some-encapsulated miR-143 [56, 57]. Also, doxorubicin 
loaded into exosomes or exosome-mimetic nanovesicles 
inhibited the growth of colon and breast cancer xenograft 
tumors in vivo [58, 59]. Furthermore, by targeting imma-
ture dendritic cell exosomes directly to the tumor tissue, 
the efficacy of doxorubicin was greatly enhanced. The 
enhanced efficacy was accompanied with significantly 
less adverse effects on the main organ systems, imply-
ing that delivery via exosomes might decrease the major 
downside of this chemotherapeutic drug [58]. These 
results suggest an opportunity for using exosomes as a 
carrier of treatments of cancer. Considering exosomes’ 
rate of clearance and biodistribution, administration 
routes used for exosome drug delivery should be studied 
in future.
Thirdly, because exosomes have a specific cell tropism 
according to their characteristics, they can be used to tar-
get specific tissues or organs. For example, two studies 
bioengineered a well-characterized exosomal membrane 
protein (Lamp2b) to express a targeting peptide imme-
diately below the signal peptide sequence, which secured 
the correct insertion of the protein into the exosome 
membrane and avoided cleavage of important regions 
in the targeting peptide sequence. Using this method, 
the targeting peptides RVG and iRGD were successfully 
inserted into exosomes from immature dendritic cells to 
target either brain or tumor tissues [58, 60]. Both stud-
ies found that usage of a targeting peptide on a Lamp2b 
pedestal significantly increased the specificity of the 
treatment, enhanced the cellular uptake of exosomes 
in the tissues of interest, and decreased the toxicity of 
drugs delivered by exosomes. These results suggest that 
exosomes modified by targeting ligands can be used ther-
apeutically for the delivery of an anti-cancer substance 
to tumors, thus having great potential value for clinical 
applications.
At last, because of the role of exosomes in the immune 
system, exosome based cell free vaccines could represent 
an alternative to dendritic cell (DC) therapy for suppress-
ing tumor growth. By transfecting B16 melanoma cells 
with a plasmid encoding the Mycobacterium tuberculosis 
antigen, Koyama et  al. collected the secreted exosomes 
bearing the pathogenic antigen, and then injected the 
exosomes into foot pads of mice. As a result, they found 
these exosomes significantly (p  <  0.05) evoked cellu-
lar immunity against B16 tumor cells, and suppressed 
(p < 0.001) tumor growth in syngeneic B16 tumor-bear-
ing mice [61]. This suggests that exosomes bearing both 
tumor antigens and the Mycobacterium tuberculosis 
antigen have a high potential as a candidate for cancer 
vaccine to overcome the immune escape by tumor cells. 
Similarly, by loading Dex with IFN-γ, MHC class I- and 
class II-restricted cancer antigens, Besse et al. carried out 
a phase II clinical trial to test these exosomes as main-
tenance immunotherapy after induction chemotherapy 
in patients bearing inoperable NSCLC. And at last they 
confirmed the capacity of Dex to boost the NK cell 
arm of antitumor immunity in patients with advanced 
NSCLC [34]. Although these findings are encouraging, 
some researchers observed that only a small percentage 
of patients presented transient stabilisation of the disease 
[62]. This implies that more studies are needed to evalu-
ate the role of exosomes in immune therapy of cancer.
Use of exosomes as prognostic biomarkers for cancers
Each tumor is characterized by a specific miRNA or pro-
tein profile. Increasing evidence has shown that exosomal 
miRNAs and proteins are positively correlated with the 
stage and degree of tumor progression. Vered et al. inves-
tigated caveolin-1 (CAV1) in exosomes of tongue squa-
mous cell carcinoma (TSCC) and its association with 
clinical outcomes. As a result, they found that expression 
of CAV1 in TSCC had a higher score in exosomes than 
in the tumor cells and a negative impact on recurrence 
(p = 0.01) and survival (p = 0.003), which suggested that 
accumulation of CAV1 in exosomes had a negative prog-
nostic value in TSCC [63]. In addition, Ye et al. isolated 
exosomes from serum of healthy donors and patients 
with nasopharyngeal carcinoma (NPC). They found that 
miR-24-3p was markedly enriched in exosomes from 
patients with NPC compared with those from healthy 
donors; and the serum exosomal miR-24-3p level was 
correlated with worse disease-free survival of patients 
(p  <  0.05) [37]. These allow the use of TD exosomes as 
novel prognostic markers.
Summary
Exosomes, as small particles, can function as key trans-
porters for intercellular communication and for modu-
lating immune responses, owing to their content of 
proteins and genetic material that mirror their cells of 
origin. Tumors have hijacked this mechanism of inter-
cellular communication to aid in their growth, progres-
sion, and dissemination [64]. TD-exosomes can construct 
a fertile environment to support tumor proliferation, 
angiogenesis, invasion and premetastatic niche prepa-
ration. TD-exosomes also may facilitate tumor growth 
and metastasis by inhibiting immune surveillance and by 
increasing chemoresistance via removal of chemothera-
peutic drugs (Table  1). Therefore, TD-exosomes might 
be potential targets for therapeutic interventions via 
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their modification or removal. For example, exosomes 
can serve as specific delivery vehicles to tumors of 
drugs, small molecules, or agents of prevention and 
gene therapy. Furthermore, the biomarkers detected 
in exosomes of biological fluids imply a potential for 
exosomes in the early detection and diagnosis, prediction 
of therapeutic efficacy, and determining the prognosis of 
cancer (Table  2). However, many problems still need to 
be resolved, such as (1) The use of exosomes as cancer 
biomarkers is technically limited by their size, heteroge-
neity and the need for extensive purification and label-
ling; (2) How to use exosomes as delivery vehicles loaded 
with anticancer drugs effectively in clinics? and (3) How 
to block the negative effects of TD exosomes on tumors? 
Table 1 The relationships between exosomes and cancer
MSC mesenchymal stem cell, IGF-IR insulin like growth factor-I receptor, FAK focal adhesion kinase, AR androgen receptor, MM multiple myeloma, STAT3 signal 
transducer and activator of transcription 3, OSA obstructive sleep apnea, TLR toll-like receptor, APAF1 apoptotic protease activating factor-1
Study ID (author, year) Study design Main results
Gu et al., 2016 [14] The effects of MSC‑exosomes on gastric 
cancer are evaluated, and the possible 
mechanisms are explored
Exosomes derived from human mesenchymal stem cells promote 
gastric cancer cell growth and migration by activating the Akt 
pathway
DeRita et al., 2016 [20] The effects of exosomes derived from prostate 
cancer cell on tumors and the contents of 
these exosomes are evaluated
Src, IGF‑IR, and FAK are enriched in exosomes from the AR‑positive 
cell line C4‑2B, which are implicated in many aspects of tumor biol‑
ogy including angiogenesis
Wang et al., 2016 [21] The functions of MM exosomes in angiogen‑
esis and immunosuppression are explored 
in vitro and in vivo
Murine MM exosomes which carried multiple angiogenesis‑related 
proteins, enhanced angiogenesis and directly promoted endothe‑
lial cell growth by modulating several pathways such as STAT3
Khalyfa et al., 2016 [12] The effects of exosomes from OSA patients on 
human adenocarcinoma cells are evaluated
OSA induces alterations in exosomal miRNA cargo that alter the 
biological properties of TC1 lung tumor cells to enhance their 
proliferative, migratory and extravasation properties
Fabbri et al., 2012 [33] The expression level of miR‑21 and miR‑29a 
in exosomes derived from lung cancer cell 
lines and their effects on tumor immune are 
evaluated
MiR‑21 and miR‑29a are highly expressed in exosomes derived from 
lung cancer cell lines, function by binding as ligands to receptors 
of TLR family (murine TLR7 and human TLR8) in immune cells, and 
trigger a TLR‑mediated prometastatic inflammatory response that 
ultimately may lead to tumor growth and metastasis
Au Yeung et al., 2016 [42] The level of miRNA21 in exosomes isolated 
from cancer‑associated adipocytes and 
fibroblasts and its effects on ovarian cancer 
cells are evaluated
The level of miRNA21 in exosomes isolated from cancer‑associated 
adipocytes and fibroblasts is significantly higher than in those 
from ovarian cancer cells. Functional studies reveal that miR21 is 
transferred from cancer‑associated adipocytes or fibroblasts to 
the cancer cells, where it suppresses ovarian cancer apoptosis and 
confers chemoresistance by binding to APAF1
Table 2 Clinical utility of exosomes in cancer
EGFR epidermal growth factor receptor, CAV1 Caveolin-1, TSCC tongue squamous cell carcinoma
Study ID (author, year) Study design Main results
Kharmate et al., 2016 [51] The expression level of EGFR in exosomes 
derived from prostate cancer cells and pros‑
tate cancer patient serum
Presence of exosomal EGFR in prostate cancer patient exosomes may 
present a novel biomarker for measuring of the disease state
Machida et al., 2016 [52] The expression of four miRNAs (miR‑1246, miR‑
3976, miR‑4306, and miR‑4644) in salivary 
exosomes from patients with pancreatobil‑
iary tract cancer
MiR‑1246 and miR‑4644 were significantly higher expressed in the cancer 
group than those in the control group, suggesting that miRNAs in 
exosomes can be used as candidate biomarkers for tumors
Tian et al., 2014 [58] Exosomes derived from mouse immature 
dendritic cells are loaded with doxorubicin 
via electroporation
Intravenously injected exosomes deliver doxorubicin specifically to tumor 
tissues and lead to inhibition of tumor growth without overt toxicity, 
suggesting that exosomes can be used as transporters loaded with 
various anticancer drugs
Koyama et al., 2016 [61] Exosomes derived from B16 melanoma cells 
which are transfected with a plasmid encod‑
ing the Mycobacterium tuberculosis antigen 
are collected and injected into foot pads of 
mice
The modified exosomes significantly evoked cellular immunity against 
B16 tumor cells, and suppressed tumor growth in syngeneic B16 
tumor‑bearing mice, suggesting that exosomes have a high potential 
as a candidate for cancer vaccine to overcome the immune escape by 
tumor cells
Vered et al., 2015 [63] They investigate CAV1 in exosomes of TSCC 
and its association with clinical outcomes
The expression of CAV1 in TSCC had a higher score in exosomes than 
in the tumor cells and a negative impact on recurrence and survival, 
suggesting that exosomes can be used as novel prognostic biomarkers 
for tumors
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Therefore, we have a long way to go before we can fur-
ther enhance the anti-tumor therapy of exosomes and 
develop exosome-based cancer diagnostic and therapeu-
tic strategies.
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